Pharmacotherapy in sickle cell disease—state of the art and future prospects. (otvorí nové okno)

Hankins J, Aygun B.

Zdroj‎: Br J Haematol 2009;145(3):296-308.

Označenie‎: PubMed 19222472

Identifikátor digitálneho objektu‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (otvorí nové okno)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (otvorí nové okno)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Zdroj‎: Blood 2005;106(7):2269-75.

Označenie‎: PubMed 16172253

Identifikátor digitálneho objektu‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (otvorí nové okno)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (otvorí nové okno)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Zdroj‎: N Engl J Med 2020;382(26):2524-33.

Označenie‎: PubMed 32579813

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (otvorí nové okno)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (otvorí nové okno)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Zdroj‎: Br J Haematol 2013;161(6):852-60.

Označenie‎: PubMed 23590693

Identifikátor digitálneho objektu‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (otvorí nové okno)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (otvorí nové okno)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Zdroj‎: Arch Dis Child 2013;98(11):908-14.

Označenie‎: PubMed 23995076

Identifikátor digitálneho objektu‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (otvorí nové okno)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (otvorí nové okno)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Zdroj‎: Pediatrics 2008;122(6):1332-42.

Označenie‎: PubMed 19047254

Identifikátor digitálneho objektu‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (otvorí nové okno)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (otvorí nové okno)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Zdroj‎: Blood 2012;120(22):4304-10.

Označenie‎: PubMed 22915643

Identifikátor digitálneho objektu‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (otvorí nové okno)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (otvorí nové okno)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Zdroj‎: N Engl J Med 2019;380(2):121-31.

Označenie‎: PubMed 30501550

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (otvorí nové okno)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (otvorí nové okno)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Zdroj‎: J Pediatr 2002;140(2):225-9.

Označenie‎: PubMed 11865275

Identifikátor digitálneho objektu‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (otvorí nové okno)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (otvorí nové okno)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Zdroj‎: Pediatrics 2013;132(4):677-83.

Označenie‎: PubMed 23999955

Identifikátor digitálneho objektu‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (otvorí nové okno)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (otvorí nové okno)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Zdroj‎: Lancet 2011;377(9778):1663-72.

Označenie‎: PubMed 21571150

Identifikátor digitálneho objektu‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (otvorí nové okno)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (otvorí nové okno)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Zdroj‎: Lancet 2016;387(10019):661-70.

Označenie‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (otvorí nové okno)

How I use hydroxyurea to treat young patients with sickle cell anemia. (otvorí nové okno)

Ware RE.

Zdroj‎: Blood 2010;115(26):5300-11.

Označenie‎: PubMed 20223921

Identifikátor digitálneho objektu‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (otvorí nové okno)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (otvorí nové okno)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Zdroj‎: Blood 2004;103(6):2039-45.

Označenie‎: PubMed 14630791

Identifikátor digitálneho objektu‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (otvorí nové okno)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (otvorí nové okno)

Hirst C, Owusu-Ofori S.

Zdroj‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Označenie‎: PubMed 22972063

Identifikátor digitálneho objektu‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (otvorí nové okno)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (otvorí nové okno)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Zdroj‎: Lancet Haematol 2021;8(5):e323-33.

Označenie‎: PubMed 33838113

Identifikátor digitálneho objektu‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (otvorí nové okno)

Sickle cell disease. (otvorí nové okno)

Meremikwu MM, Okomo U.

Zdroj‎: BMJ Clin Evid 2011;02:2402.

Označenie‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (otvorí nové okno)

A phase 3 trial of l-glutamine in sickle cell disease. (otvorí nové okno)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Zdroj‎: N Engl J Med 2018;379(3):226-35.

Označenie‎: PubMed 30021096

Identifikátor digitálneho objektu‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (otvorí nové okno)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (otvorí nové okno)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Zdroj‎: Blood. 2023 23;141(12):1402-10.

Označenie‎: PubMed 36375125

Identifikátor digitálneho objektu‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (otvorí nové okno)

Malaria chemoprophylaxis in sickle cell disease. (otvorí nové okno)

Oniyangi O, Omari AA.

Zdroj‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Označenie‎: PubMed 17054173

Identifikátor digitálneho objektu‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (otvorí nové okno)